Maymetsi

Metformin Hydrochloride / Sitagliptin, the active ingredients in Maymetsi, are a Biguanide and a DPP‑4 inhibitor presented as a fixed‑dose combination tablet for oral administration. The medication is indicated for the management of type 2 diabetes mellitus in adult patients, helping to control elevated blood glucose levels when used as part of a comprehensive treatment plan that includes diet and exercise.

GNH USA supplies Maymetsi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and other healthcare providers worldwide.

Maymetsi, a fixed‑dose combination of metformin and sitagliptin, is used in the management of type 2 diabetes mellitus.

- Type 2 diabetes mellitus (initial therapy): provides glycemic control as first‑line treatment in combination with lifestyle measures. - Type 2 diabetes mellitus (add‑on therapy): enhances glucose lowering when metformin alone does not achieve target HbA1c. - Type 2 diabetes mellitus (metformin intolerance): offers an alternative to metformin monotherapy by combining a lower metformin dose with sitagliptin.

Adverse reactions may occur with any antidiabetic therapy and should be monitored.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools, often transient. - Abdominal discomfort: cramping or pain. - Headache: mild tension‑type headache. - Hypoglycemia (when combined with sulfonylureas or insulin): symptoms of low blood sugar. - Metallic taste: occasional altered taste perception.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Acute pancreatitis: severe abdominal pain with elevated enzymes. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Hepatic dysfunction: abnormal liver enzymes or jaundice. - Renal impairment worsening: especially in patients with pre‑existing kidney disease. - Severe hypoglycemia: profound low glucose requiring assistance.

Patients should be evaluated for safety before initiating therapy.

- Renal function assessment: ensure adequate glomerular filtration before prescribing. - Hepatic function monitoring: avoid use in severe liver disease. - Cardiovascular status: use caution in patients with congestive heart failure. - Elderly patients: start with lower doses and monitor for intolerance. - Concomitant medications: review for agents that may increase risk of hypoglycemia or lactic acidosis. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Potential drug interactions may affect efficacy or safety.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure and lactic acidosis. - Cimetidine: can increase metformin plasma concentrations. - Insulin or sulfonylureas: heightened risk of hypoglycemia.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance of metformin. - ACE inhibitors or ARBs: monitor renal function and potassium levels. - NSAIDs: can reduce renal perfusion, increasing metformin exposure.